12:55am Monday 14 October 2019

Penn Study Suggests New Recommendations to Reduce Radiation Risk from Digital Screening Mammography

PHILADELPHIA – Radiation-induced breast cancer risk from digital mammography is low for the majority of women, but risk is higher in women with large breasts, who received 2.3 times more radiation and required more views per examination to image as much of the breast as possible compared to those with small or average-sized breasts.

The study also found that screening every two years instead of annually, and beginning at age 50 instead of 40 or 45, lowers the likelihood of radiation-induced breast cancer in all women. The findings from a team of researchers including Rebecca Hubbard, PhD, an associate professor of Biostatistics in Biostatistics and Epidemiology in the Perelman School of Medicine at the University of Pennsylvania, appear online this week in Annals of Internal Medicine.

In eight screening strategies estimated using two models, the group simulated the lifetime risk of women developing radiation-induced breast cancer from digital screening mammography and dying from the disease compared to the number of deaths averted through early detection.

The group found that screening 100,000 women, ages 50 to 74, every two years, prevented 627 deaths. The radiation exposure from these screening exams, and any subsequent diagnostic work-ups, caused 27 breast cancer cases and 4 breast cancer deaths. Although screening 100,000 women annually from 40 to 74 years prevented 968 deaths, it also raised cancer risk five-fold, causing 100 additional radiation-induced breast cancers and 12 additional breast cancer deaths compared with screening every two years from age 50 to 74.

Recommendations released earlier this week by the U.S. Preventive Services Task Force, an independent panel appointed by the federal government, echo the study’s finding that women between the ages of 50 and 74 should be screened once every two years for breast cancer.

“Choosing a screening schedule that reduces harms while maintaining the benefits of more frequent screening makes screening mammography safer for all women,” Hubbard, who is also senior author on the study, said. “As our understanding of the effects of individual characteristics on harms and benefits of mammography grows, we can more effectively tailor screening strategies to minimize harms and save more lives.”

While not explicitly reviewed in the research, the findings suggest risk is also higher in those with breast implants, which require twice as many views during mammography, and/or denser breasts which require additional evaluations resulting in more radiation exposure.

The study also noted that obtaining fewer mammograms would also result in fewer false positives, which can prevent radiation exposure from possibly unneeded follow-up diagnostic mammograms.

Although women with large breasts are at greater risk, larger detectors can image women in this population with fewer views and less radiation. In addition, 3-D tomosynthesis may also lessen exposure from diagnostic evaluations if early evidence of reduced false-positives holds up in larger studies.

Co-authors on the study include lead author Diana L. Miglioretti, PhD, of University of California, Davis School of Medicine; Jane Lange, PhD, of Group Health Research Institute; Jeroen J. van den Broek, MSc, Nicolien T. van Ravesteyn, PhD, and Harry J. de Koning, PhD, of Erasmus MC University Medical Center; Christoph I. Lee, MD, MSHS of University of Washington; Dominique Ritley, MPH, Joshua J. Fenton, MD, MPH, and Joy Melnikow, MD, MPH of University of California, Davis, and Karla Kerlikowske, MD, of the San Francisco Veterans Affairs Medical Center.

This research was funded by the Agency for Healthcare Research and Quality (grant HHSA-290-2012-00015I), U.S. Preventive Services Task Force, and National Cancer Institute (grants P01CA154292, 5U01CA152958, and R03CA182986). Collection of mammography data was supported by the BCSC, which is funded by the National Cancer Institute (grants P01CA154292, HHSN261201100031C, and U54CA163303). The collection of BCSC data was supported in part by several state public health departments and cancer registries throughout the United States. Click here for a full description of these sources. Primary research and data collection supported by the National Cancer Institute (grants U01 CA80098, U01 CA80098-S1, U01 CA79778, and U01 79778-S1).

For more information, see full UC Davis release.


Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation’s first medical school) and the University of Pennsylvania Health System, which together form a $5.3 billion enterprise.

The Perelman School of Medicine has been ranked among the top five medical schools in the United States for the past 17 years, according to U.S. News & World Report‘s survey of research-oriented medical schools. The School is consistently among the nation’s top recipients of funding from the National Institutes of Health, with $409 million awarded in the 2014 fiscal year.

The University of Pennsylvania Health System’s patient care facilities include: The Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center — which are recognized as one of the nation’s top “Honor Roll” hospitals by U.S. News & World Report — Chester County Hospital; Lancaster General Health; Penn Wissahickon Hospice; and Pennsylvania Hospital — the nation’s first hospital, founded in 1751. Additional affiliated inpatient care facilities and services throughout the Philadelphia region include Chestnut Hill Hospital and Good Shepherd Penn Partners, a partnership between Good Shepherd Rehabilitation Network and Penn Medicine.

Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2014, Penn Medicine provided $771 million to benefit our community.

Share on:

MORE FROM Breast Cancer

Health news